Minerva Neurosciences
NERV
22 hedge funds and large institutions have $3.31M invested in Minerva Neurosciences in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 22 → 22 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
1.91% less ownership
Funds ownership: 29.84% → 27.93% (-1.9%)
29% less capital invested
Capital invested by funds: $4.63M → $3.31M (-$1.32M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Apella Capital
West Hartford,
Connecticut
|
+$40.7K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$40K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$3.17K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.37K |
| 5 |
FFA
Farther Finance Advisors
San Francisco,
California
|
+$197 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$238K |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$81.9K |
| 3 |
Renaissance Technologies
New York
|
-$27.6K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$25.4K |
| 5 |
Morgan Stanley
New York
|
-$10.1K |
NERV Hedge Fund Activity: Q1 2025 in Review
22 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Minerva Neurosciences (NERV) for Q1 2025, worth a combined $3.31M — down 29% from $4.63M a quarter earlier.
Fund positioning in NERV was balanced in Q1 2025: 3 funds opened new positions, 3 closed out, 4 added to existing stakes and 4 trimmed.
The largest buyer was Apella Capital, opening a new position worth an estimated $40.7K. The largest seller was UBS O'Connor, exiting entirely with an estimated $238K sold.
- 22 institutional investors held Minerva Neurosciences (NERV) as of Q1 2025, unchanged from Q4 2024.
- Funds reported $3.31M of Minerva Neurosciences stock for Q1 2025, down 29% quarter-over-quarter.
- 3 funds opened new Minerva Neurosciences positions in Q1 2025 and 3 closed out, a net change of 0 holders.
- The largest Minerva Neurosciences buyer in Q1 2025 was Apella Capital, an estimated $40.7K added.
- The largest Minerva Neurosciences seller in Q1 2025 was UBS O'Connor, an estimated $238K sold.
Based on aggregated 13F filings for Q1 2025.